MaxCyte, Inc. operates the Flow Electroporation® platform used in next-generation cell and gene therapies. Despite technological leadership developed over two decades, annual revenue declined from $44.3 million in 2022 to $33.0 million in 2025, with operating losses exceeding $50 million annually. The company faces growth constraints related to customer concentration, competition, and the early-stage nature of its biopharma customers. Investments continue in R&D and manufacturing scale-up, including the recent launch of the DTx platform in early 2026. MaxCyte maintains strong liquidity but remains unprofitable with ongoing negative cash flows.